AvalehtGRAL • NASDAQ
add
Grail Inc
Viimane sulgemishind
17,52 $
Aasta vahemik
12,33 $ - 21,47 $
Turuväärtus
549,56 mln USD
Keskmine maht
605,16 tuh
P/E suhe
-
Dividendimäär
-
Põhibörs
NASDAQ
Finantsandmed
Kasumiaruanne
Käive
Puhastulu
| (USD) | sept 2024info | Y/Y muutus |
|---|---|---|
Käive | 28,65 mln | 38,27% |
Põhitegevusega seonduv kulu | 175,74 mln | −12,27% |
Puhastulu | −125,69 mln | 85,90% |
Puhaskasumimarginaal | −438,67 | 89,80% |
Puhaskasum aktsia kohta | −3,50 | — |
EBITDA | −125,27 mln | 18,72% |
Tõhus maksumäär | 27,10% | — |
Bilansiaruanne
Kogu vara
Kõik kohustused
| (USD) | sept 2024info | Y/Y muutus |
|---|---|---|
Sularaha ja lühiajalised investeeringud | 853,55 mln | — |
Kogu vara | 3,12 mld | — |
Kõik kohustused | 530,32 mln | — |
Kogu omakapital | 2,59 mld | — |
Emiteeritud aktsiate arv | 33,60 mln | — |
Hinna ja väärtuse suhe P/B | 0,22 | — |
Varade tasuvus | −12,88% | — |
Kapitali tasuvus | −15,14% | — |
Rahavoog
Raha ja raha ekvivalentide muutus
| (USD) | sept 2024info | Y/Y muutus |
|---|---|---|
Puhastulu | −125,69 mln | 85,90% |
Põhitegevuse rahakäive | −104,58 mln | 33,60% |
Investeeringute raha | −971,00 tuh | 68,36% |
Finantseerimise raha | 0,00 | −100,00% |
Raha ja raha ekvivalentide muutus | −105,29 mln | −21,33% |
Tasuta rahavoog | −36,90 mln | — |
Teave
GRAIL, Inc. is an American biotechnology company based in Menlo Park, California. It was previously a subsidiary of Illumina started as a startup seeking to develop an early cancer screening test for people who do not have symptoms.
Grail was spun-out from Illumina on June 24, 2024.
Their liquid biopsy was launched in June 2021 and is called the Galleri test. Promoted as groundbreaking, the test performed poorly in testing and Grail has subsequently faced discontent and legal action from investors claiming they have been misled about the test's potential. Wikipedia
Asutatud
2015
Veebisait
Töötajate arv
1 170
